[{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"34e7c443-a4b5-4fa2-810c-e931f9bf2ab9","acronym":"SGNEGFRd2-001","url":"https://clinicaltrials.gov/study/NCT05983133","created_at":"2023-08-09T14:09:24.911Z","updated_at":"2025-02-25T13:55:26.636Z","phase":"Phase 1","brief_title":"A Study of SGN-EGFRd2 in Advanced Solid Tumors","source_id_and_acronym":"NCT05983133 - SGNEGFRd2-001","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046052"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-02-20"},{"id":"8b904991-7019-4cce-9e04-2e7482447f70","acronym":"","url":"https://clinicaltrials.gov/study/NCT05815173","created_at":"2023-04-18T15:04:23.224Z","updated_at":"2025-02-25T14:09:36.744Z","phase":"Phase 1","brief_title":"Ladarixin With Sotorasib in Advanced NSCLC","source_id_and_acronym":"NCT05815173","lead_sponsor":"NYU Langone Health","biomarkers":" KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation","tags":["KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • ladarixin (DF-2156A)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-19"},{"id":"bbff33d0-fbb7-447e-b61a-196b5c2984ea","acronym":"ALTA-3","url":"https://clinicaltrials.gov/study/NCT03596866","created_at":"2021-01-18T17:41:06.342Z","updated_at":"2025-02-25T14:07:13.042Z","phase":"Phase 3","brief_title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT03596866 - ALTA-3","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 02/27/2024","primary_completion_date":" 02/27/2024","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-19"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"f02c2f2b-a093-410f-90e0-01cc532b5f16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04786093","created_at":"2021-03-08T12:53:40.787Z","updated_at":"2025-02-25T15:11:58.304Z","phase":"Phase 2","brief_title":"Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC","source_id_and_acronym":"NCT04786093","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion","tags":["PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-13"},{"id":"a33d484d-46c6-4556-93ba-bc9cbf506681","acronym":"SAKK 19/17","url":"https://clinicaltrials.gov/study/NCT03620669","created_at":"2021-01-18T17:47:28.561Z","updated_at":"2025-02-25T15:17:49.744Z","phase":"Phase 2","brief_title":"1st Line Durvalumab in PS 2 NSCLC Patients","source_id_and_acronym":"NCT03620669 - SAKK 19/17","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK rearrangement • ALK fusion","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK rearrangement • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/04/2018","start_date":" 12/04/2018","primary_txt":" Primary completion: 01/19/2023","primary_completion_date":" 01/19/2023","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-12"},{"id":"917b48fd-6760-442b-9dca-351ad6f6d491","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299141","created_at":"2021-01-17T17:53:09.705Z","updated_at":"2025-02-25T15:33:17.802Z","phase":"Phase 2","brief_title":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02299141","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • ALK • TP53 • FLT1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • RET rearrangement","tags":["EGFR • ALK • TP53 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/07/2015","start_date":" 05/07/2015","primary_txt":" Primary completion: 01/09/2020","primary_completion_date":" 01/09/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-11"},{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"9581c2d9-b454-4592-b3f9-10aa36b40702","acronym":"ANVIL","url":"https://clinicaltrials.gov/study/NCT02595944","created_at":"2021-01-18T12:36:00.436Z","updated_at":"2025-02-25T16:43:58.258Z","phase":"Phase 3","brief_title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","source_id_and_acronym":"NCT02595944 - ANVIL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 903","initiation":"Initiation: 07/22/2016","start_date":" 07/22/2016","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"dab562b9-279d-4fe8-b2fc-7ee0c721ed02","acronym":"KUNPENG-2","url":"https://clinicaltrials.gov/study/NCT05989542","created_at":"2023-08-14T14:10:14.391Z","updated_at":"2025-02-25T16:40:06.600Z","phase":"Phase 3","brief_title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","source_id_and_acronym":"NCT05989542 - KUNPENG-2","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" EGFR • KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement","tags":["EGFR • KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"f728f5a5-7b35-4430-bcb8-753e01deecd0","acronym":"ALCHEMIST","url":"https://clinicaltrials.gov/study/NCT02193282","created_at":"2021-01-18T10:14:33.510Z","updated_at":"2025-02-25T16:43:51.158Z","phase":"Phase 3","brief_title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","source_id_and_acronym":"NCT02193282 - ALCHEMIST","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 10/10/2026","primary_completion_date":" 10/10/2026","study_txt":" Completion: 10/10/2026","study_completion_date":" 10/10/2026","last_update_posted":"2025-02-06"},{"id":"6a19572d-9fdc-40c8-bddf-32eccbc29186","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808662","created_at":"2021-01-18T18:49:15.420Z","updated_at":"2025-02-25T16:31:44.180Z","phase":"Phase 2","brief_title":"Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung","source_id_and_acronym":"NCT03808662","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • HER-2 • ER • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["EGFR • HER-2 • ER • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-05"},{"id":"2556a800-12ac-4ffc-b124-64c3995bab28","acronym":"AVANZAR","url":"https://clinicaltrials.gov/study/NCT05687266","created_at":"2023-01-18T15:59:54.978Z","updated_at":"2025-02-25T17:31:49.301Z","phase":"Phase 3","brief_title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05687266 - AVANZAR","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • BRAF • ALK • ROS1 • TACSTD2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1350","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-30"},{"id":"41be4368-ac8d-41a5-97f4-07c00abcbd42","acronym":"ADAPT-E","url":"https://clinicaltrials.gov/study/NCT04585477","created_at":"2023-03-02T18:01:37.004Z","updated_at":"2025-02-25T14:59:23.663Z","phase":"Phase 2","brief_title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","source_id_and_acronym":"NCT04585477 - ADAPT-E","lead_sponsor":"Stanford University","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"4a460451-5964-49e7-8b50-20d79d3f9b89","acronym":"HEMONC CIRM IST Lung","url":"https://clinicaltrials.gov/study/NCT03546361","created_at":"2021-01-18T17:27:35.511Z","updated_at":"2025-02-25T16:07:56.707Z","phase":"Phase 1","brief_title":"CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03546361 - HEMONC CIRM IST Lung","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ad-CCL21-DC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 01/11/2026","primary_completion_date":" 01/11/2026","study_txt":" Completion: 01/11/2027","study_completion_date":" 01/11/2027","last_update_posted":"2025-01-14"},{"id":"db3994c6-3749-4a13-acb1-99aa40802cdb","acronym":"CORAL-Lung","url":"https://clinicaltrials.gov/study/NCT05000710","created_at":"2021-08-11T14:55:34.487Z","updated_at":"2025-02-25T15:00:02.742Z","phase":"Phase 2","brief_title":"Concomitant Radiotherapy, Tremelimumab \u0026 Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy","source_id_and_acronym":"NCT05000710 - CORAL-Lung","lead_sponsor":"Sheba Medical Center","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ALK translocation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-05"},{"id":"9ef28cb0-6b0e-4242-8ea3-6de25a48faed","acronym":"LEAP-008","url":"https://clinicaltrials.gov/study/NCT03976375","created_at":"2021-01-18T19:33:26.274Z","updated_at":"2025-02-25T13:35:24.264Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)","source_id_and_acronym":"NCT03976375 - LEAP-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • ALK • ROS1","pipe":" | ","alterations":" KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation","tags":["EGFR • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 422","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-11-18"},{"id":"55fca2cd-0dc1-47d8-86f5-df409157addc","acronym":"ALKALINE","url":"https://clinicaltrials.gov/study/NCT04127110","created_at":"2021-01-18T20:09:41.572Z","updated_at":"2025-02-25T12:37:27.279Z","phase":"Phase 2","brief_title":"Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients","source_id_and_acronym":"NCT04127110 - ALKALINE","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-11-05"},{"id":"7c4c2c5c-0d9e-41b0-96b2-8600aa7be62a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318938","created_at":"2021-01-18T20:55:43.511Z","updated_at":"2025-02-25T14:51:44.818Z","phase":"Phase 2","brief_title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","source_id_and_acronym":"NCT04318938","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" ALK • TP53","pipe":" | ","alterations":" TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation","tags":["ALK • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 01/16/2026","primary_completion_date":" 01/16/2026","study_txt":" Completion: 01/16/2026","study_completion_date":" 01/16/2026","last_update_posted":"2024-10-14"},{"id":"c486812a-1158-4f0a-ac01-34c0020a4203","acronym":"","url":"https://clinicaltrials.gov/study/NCT02955758","created_at":"2021-01-18T14:31:17.121Z","updated_at":"2025-02-25T16:05:24.271Z","phase":"Phase 2","brief_title":"Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02955758","lead_sponsor":"Joel Neal","biomarkers":" PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK rearrangement","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 04/09/2024","primary_completion_date":" 04/09/2024","study_txt":" Completion: 04/09/2024","study_completion_date":" 04/09/2024","last_update_posted":"2024-10-09"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"}]